Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Cochlear ( (AU:COH) ) is now available.
Cochlear Limited has received FDA approval for its Cochlear™ Nucleus® Nexa™ System and Nucleus Kanso® 3 and Kanso® 3 Nexa Sound Processors, with plans to launch these products in the US by the end of the first quarter of FY26. This approval marks a significant milestone for Cochlear, potentially enhancing its market position in the US and offering advanced hearing solutions to its stakeholders.
The most recent analyst rating on (AU:COH) stock is a Sell with a A$272.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
More about Cochlear
Cochlear Limited is a company operating in the medical device industry, specializing in implantable hearing solutions. Its primary products include cochlear implants and sound processors, focusing on improving hearing for individuals with severe to profound hearing loss.
YTD Price Performance: 4.67%
Average Trading Volume: 192,973
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$19.68B
For an in-depth examination of COH stock, go to TipRanks’ Overview page.